Global Viral Vector and Plasmid DNA Manufacturing Market Report 2023-2028: Industry Forecasted at $10.14 Billion by 2028, Dominated by Oxford Biomedica, Cognate BioServices, and Cell & Gene Therapy Catapult

Dublin, Feb. 20, 2024 (GLOBE NEWSWIRE) -- The "Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Size, Share, Trends Opportunity, and Forecast 2018-2028" report has been added to's offering.

The Global Viral Vector and Plasmid DNA Manufacturing Market has been showcased for its remarkable surge, valued at USD 5.49 billion in 2022, and is projected to continue along a trajectory of impressive growth. With the utilization of viral vectors and plasmid DNA becoming increasingly critical in the fields of gene therapy, vaccine production, and genetic engineering, stakeholders across biotechnology and biopharmaceutical landscapes are keen on the opportunities and forecasts within this sector.

Amid the growing investment in cutting-edge gene therapy research and development, the market is set to experience a compound annual growth rate (CAGR) of 10.89% through 2028. This momentum is fueled by the ever-expanding potentials of gene therapy to address genetic disorders, rare diseases, and a burgeoning array of medical conditions requiring novel forms of treatment.

Key Market Drivers

The surge in activities within the market is attributable to an array of factors. From advancements in genetic engineering, represented by game-changing technologies like CRISPR-Cas9, to the biopharmaceutical industry's evolution resulting in efficient drug production techniques - a confluence of dynamism shapes the viral vector and plasmid DNA manufacturing ecosystem.

Increased focus and capital injection into gene therapy's capabilities have catalyzed a broad scope of clinical applications that extends to the treatment of cancers and neurodegenerative disorders. Regulatory agencies have also been instrumental in fostering this environment by offering expedited approvals and supportive engagement in product development.

Technological Advancements

Technological strides in manufacturing modalities offer another pillar sustaining the market's robustness. Innovations in single-use bioreactors, cell culture media, and purification techniques are enhancing yield, purity, and the overall cost-effectiveness of viral vector and plasmid DNA production processes. These advancements ensure that the industry's pace matches the growing demand and complexity of gene therapy requirements.

Key Market Challenges

Nonetheless, the path to a fully actualized market is not devoid of hurdles. The high costs associated with complex manufacturing processes and the necessity to remain compliant with stringent regulatory standards add layers of financial pressure. Moreover, ethical questions tied to genetic manipulation and societal considerations about access and consent present ongoing dialogues that require conscientious attention.

Regional Insights

The largest market share is held by North America, a testament to the region's mature biopharmaceutical landscape. With a significant number of cutting-edge trials, deep investments, and a well-developed infrastructure for gene therapy development, North America sets the tone for global advancements in viral vector and plasmid DNA manufacturing.

The report's comprehensive market analysis provides invaluable insights into product type trajectories and application trends, offering a detailed breakdown of the segments and regions driving growth within the Global Viral Vector and Plasmid DNA Manufacturing Market. Amid these extensive developments and future potentials, the industry stands on the cusp of transformational advancements that hold the key to breakthrough therapies and medical innovations.

Key Attributes

Report AttributeDetails
No. of Pages182
Forecast Period2022-2028
Estimated Market Value (USD) in 2022$5.49 Billion
Forecasted Market Value (USD) by 2028$10.14 Billion
Compound Annual Growth Rate10.8%
Regions CoveredGlobal

A selection of companies mentioned in this report includes:

  • Oxford Biomedica PLC
  • Cognate BioServices Inc.
  • Cell and Gene Therapy Catapult Ltd.
  • FinVector Vision Therapies
  • Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
  • SIRION Biotech GmbH
  • Merck KGaA Inc.
  • Thermo Fisher Scientific
  • Uniqure N.V.
  • Catalent Inc.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Contact Data